La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Upexi Bilan de santé

Santé financière contrôle des critères 1/6

Upexi possède un total de capitaux propres de $22.1M et une dette totale de $26.7M, ce qui porte son ratio d'endettement à 120.9%. Son actif total et son passif total sont $56.5M et de $34.5M.

Informations clés

120.9%

Ratio d'endettement

US$26.66m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$498.29k
Fonds propres	US$22.06m
Total du passif	US$34.45m
Total des actifs	US$56.51m

Mises à jour récentes de la santé financière

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de UPXI ( $16.8M ) ne couvrent pas ses passifs à court terme ( $24.2M ).

Passif à long terme: Les actifs à court terme de UPXI ( $16.8M ) dépassent ses passifs à long terme ( $10.3M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de UPXI ( 118.6% ) est considéré comme élevé.

Réduire la dette: Données insuffisantes pour déterminer si le ratio d'endettement de UPXI a diminué au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: UPXI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: UPXI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de diminuer à un taux historique de 16.2 % chaque année

Upexi Bilan de santé

Santé financière contrôle des critères 1/6

Informations clés

Mises à jour récentes de la santé financière

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. announced delayed 10-Q filing

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. announced delayed 10-Q filing

Recent updates

Insufficient new directors

David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

E-Core Holdings, LLC acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines